← Back to All Filings

Greenwich LifeSciences CEO & CFO Buys $51.7K in Company Stock

Low SignificanceDecember 19, 2025 at 7:02:03 AM EST

Greenwich LifeSciences, Inc.

$GLSI4CIK: 0001799788

Subscribe to track GLSI

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Greenwich LifeSciences CEO & CFO Buys $51.7K in Company Stock

Company: Greenwich LifeSciences, Inc. (GLSI) Form: 4 | Filed: 2025-12-19 Significance: Low

Insider: Patel Snehal Title: CEO and CFO | Relationship: Director, Officer, 10% Owner

Transaction: • Type: Buy • Shares: 4,100 • Price: $12.62 • Value: $51,742 • Owned After: 5,592,202

Key Insight: The CEO made a small, direct purchase of common stock, representing a negligible fraction of the company's market cap and a minor addition to his substantial existing holdings.

Market Context: This is a routine open-market purchase by a key insider, often seen as a minor confidence signal but not financially material given the transaction's small size.

View Full Filing

This is PUBLIC SEC data for educational purposes. Not investment advice.

Comprehensive Analysis

SEC Filing Analysis: Greenwich LifeSciences, Inc. (GLSI)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: The CEO, CFO, Director, and 10% owner of Greenwich LifeSciences made a small open-market purchase of common stock valued at approximately $51,742.
  • Market Impact: The transaction is not material enough to likely influence the market, representing only 0.043% of the company's market capitalization.

Company Information

FieldValue
CompanyGreenwich LifeSciences, Inc.
Ticker SymbolGLSI
CIK0001799788
IndustryPHARMACEUTICAL PREPARATIONS [2834]

Insider Information

FieldValue
NamePatel Snehal
CIK0001806920
Title/PositionCEO and CFO
RelationshipDirector, Officer, 10% Owner

Transaction Details

FieldValue
Form Type4
Transaction Date2025-12-18
Transaction CodeP (Open market purchase)
Security TypeCommon Stock
Shares Involved4,100
Price Per Share$12.62
Total Value$51,742
Shares Owned After5,592,202
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$51,742
% of Market Cap0.043%
Shares Transacted4,100
% of Shares OutstandingNot available
Post-Transaction Ownership5,592,202 shares
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: With a market capitalization of $120 million, this $51,742 transaction is financially insignificant for the company.
  • Ownership Concentration: Mr. Patel already holds a very large position of over 5.5 million shares. This purchase of 4,100 shares is a minor addition to his existing stake.
  • Transaction Significance: The purchase is considered low significance due to its small value relative to both the company's market cap and the insider's existing holdings.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: While insider buying can be a positive signal, the size of this transaction is too small to be considered a strong vote of confidence or to have a meaningful impact on stock price.

Volume & Sentiment

  • Expected Volume Impact: Negligible. The transaction size is unlikely to affect trading volume.
  • Sentiment Indicator: Neutral. The purchase is too small to be considered a bullish signal.
Topics:#SECFiling#InsiderTrading#GLSI#GreenwichLifeSciences#Form4#InsiderBuy#StockMarket#Investing#CEO

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.